Report Categories
View AllRecent Articles
View All
Nktr Stock Analysis Nektar Therapeutics Up 1.69 Percent Near 77 Dollar Level 20260403 1
OSRH Q4 2025 Earnings EPS Miss of 569 Triggers Stock Decline
EXLS Q1 2026 Earnings EPS Beat by 62 Amid Solid Execution
OSBC Q1 2026 Earnings EPS Misses Estimates Amid Challenging Environment
ADTX Q3 2025 Earnings Significant Loss per Share Exceeds Expectations Stock Plunges
TSS Inc Q1 2026 Earnings Strong EPS Surprise of 170 Outpaces Estimates
SpaceX IPO Could Bring Elon Musks Space Venture into Mainstream Retirement Accounts
LTC Q1 2026 Earnings EPS Misses Estimates Amid Solid Operational Trends
Tariffs in 2025 Potential ShortRun Effects on the US Economy
Spyre Therapeutics Inc Q1 2026 Earnings Missed Estimates as Clinical Pipeline Advances
Tenable Holdings Q1 2026 Earnings EPS Surges Past Estimates Stock Gains 879
NGEN Q3 2025 Earnings NarrowerThanExpected Loss Per Share Amid Ongoing Clinical Development
AMLX Q1 2026 Earnings WiderthanExpected Loss Reflects Ongoing Pipeline Transition
XENE Q1 2026 Earnings EPS Beat in PreRevenue Biotech Stock Edges Higher
Caesarstone Ltd CSTE Q1 2026 Earnings NarrowerThanExpected Loss Signals Operational Discipline Amid Challenging Markets
Valley National Bancorp VLYPN Q1 2026 Earnings Preferred Stock Supported by EPS Beat and Stable Operations
Cybin Inc HELP Q1 2026 Earnings Significant EPS Miss Amid Clinical Progress
GRDN Q1 2026 Earnings EPS Misses Estimates Stock Edges Lower on Operational Headwinds